Skip Navigation

Anticholinergics, Amantadine, other Parkinson's disease medications

Important! You should always read carefully the information leaflet that comes with your medication before you start using it. Always check with your doctor or other healthcare professional before altering any of your medications or taking over-the-counter medications as they can interfere with Parkinson’s medications and may have unwanted side effects. Remember also to tell your doctor if you take over-the-counter drugs that can be bought without a prescription.


What you should know about your Parkinson's medication

Each medication has its own particular properties and important considerations to be aware of. Below are some key aspects to think about before you start taking your medication. Detailed information regarding these can be found in the Patient Information Leaflet (PIL):

  • what is it and what is it used for?
  • special warnings and precautions
  • how to take it
  • possible side effects
  • contraindications (when not to use it)
  • interaction with other medication(s)
  • what to do if you forget to take a dose
  • what to do if you take more than you should
  • possible effects on your ability to drive or use machinery
  • safety in pregnancy and breast-feeding
  • how to store.
Parkinson's medication overview
Generic name Brand name ®

Anticholinergics

  • Benztropine
  • Orphenadrine
  • Procyclidine
  • Trihexyphenidyl (formerly benzhexol)
  • Cogentin
  • Disipal
  • Apricolin
    Kemadrin
  • Broflex

Amantadine

  • Amantadine
  • Symmetrel

Pending classification (both dopaminergic & non dopaminergic actions)

  • Safinamide
  • Xadago

Anticholinergics

The active ingredient in Disipal® Tablets belongs to the group of medicines called anticholinergic agents. Disipal® Tablets are used in the treatment of all forms of Parkinson’s, a condition which can cause uncontrollable trembling of the hands, and other difficulties of movement, for example in standing or walking. Anticholinergic agents are also used when other medicines have caused these problems.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Disipal®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

Amantadine

Symmetrel® is a dopaminergic drug which means it can increase the levels of certain chemicals which transmit impulses in the nervous system, including the brain. It is used to treat Parkinson’s by improving muscle control and reducing stiffness, shakiness and shuffling. 

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Symmetrel®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

Pending classification

Xadago is used in addition to levodopa (a medicine commonly used to treat the symptoms of Parkinson’s) either alone or in combination with other medicines for Parkinson’s. It is used in patients with mid- to late-stage Parkinson’s who experience ‘motor fluctuations’.

Xadago contains the active substance safinamide. 

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Xadago®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website. 

  • Xadago 50mg and 100mg film-coated Tablets - Download PIL 

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

European Public Assessment Report (EPAR)

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

  • Xadago® European Public Assessment Report (EPAR) - Read report
Back to top